Pipeline

Programs

Athos Therapeutics is currently advancing two preclinical programs for patients with Ulcerative Colitis & Crohn’s Disease. Furthermore, Athos is pursuing additional discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases and cancer.

Disease/Indication

Compound

Discovery

Preclinical

Phase 1

Inflammatory Bowel Diseases & Systemic Lupus Erythematosus

ATH-63

Inflammatory Bowel Diseases & Atopic Dermatitis

ATH-105

Acute Myeloid Leukemias & Gastrointestinal Cancers

ATH-150